Kenvue (KVUE) Stock
Consumer health spin-off with trusted household brands. Here's the price, business snapshot, and what's worth knowing about Kenvue in November 2026.
Kenvue Inc (KVUE) is a consumer-health spin-off that houses a broad portfolio of over‑the‑counter medicines, personal‑care and skin‑care products sold through retail and online channels. With a market capitalisation of about $28.65 billion, the business leans on established household brands that often produce recurring demand and relatively predictable cash flows. Investors should note the trade‑offs: brand strength and geographic diversification can support resilience, but margins are sensitive to commodity, manufacturing and marketing costs, and the company faces competition and regulatory scrutiny in different markets. As a recently listed company, Kenvue’s stock can show volatility while the market judges its standalone prospects. This summary is general educational information, not personalised financial advice; values can rise or fall and past performance is not a guide to the future. Consider your objectives and risk tolerance before making investment decisions.
Why It’s Moving
Kenvue Beats Q3 Estimates as S&P 500 Removal and Kimberly-Clark Merger Loom
- Q3 EPS of $0.29 surpassed consensus estimates of $0.28, marking the fourth consecutive quarter of net and organic sales growth driven by strong performance in Self Care and Essential Health segments.
- CEO Kirk Perry highlighted disciplined execution and margin expansion, noting that results reflect continued momentum despite broader consumer spending pressures.
- S&P Dow Jones Indices confirmed Kenvue will be replaced by Okta in the S&P 500 effective November 4, coinciding with the final stages of Kimberly-Clark’s $40 billion acquisition deal.
Kenvue Beats Q3 Estimates as S&P 500 Removal and Kimberly-Clark Merger Loom
- Q3 EPS of $0.29 surpassed consensus estimates of $0.28, marking the fourth consecutive quarter of net and organic sales growth driven by strong performance in Self Care and Essential Health segments.
- CEO Kirk Perry highlighted disciplined execution and margin expansion, noting that results reflect continued momentum despite broader consumer spending pressures.
- S&P Dow Jones Indices confirmed Kenvue will be replaced by Okta in the S&P 500 effective November 4, coinciding with the final stages of Kimberly-Clark’s $40 billion acquisition deal.
Sixth Month Growth Performance
When is the next earnings date for KENVUE INC (KVUE)?
No confirmed upcoming earnings date has been announced for KVUE as of November 2, 2026. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's release, the next report is expected in February 2027. This anticipated release will cover the fourth fiscal quarter and full-year results for 2026. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Kenvue's stock with a target price of $20.82, indicating modest growth.
Financial Health
Kenvue Inc is showing strong revenue and profitability, supported by solid cash flow generation.
Dividend
Kenvue Inc's dividend yield of 4.3% offers a reasonable return for dividend-seeking investors. If you invested $1000, you would be paid $43 a year in dividends (based on the last 12 months).
Baskets Featuring KVUE
Global Pharma Titans | Brazil Healthcare Investment
Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.
Published: 16 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady cash flows
Household brands often produce repeat purchases that can support predictable revenue, though margins may fluctuate with input and marketing costs.
Global footprint
Sales across mature and emerging markets diversify exposure; local competition and currencies add complexity for investors to monitor.
Product innovation matters
Investment in new formulations, packaging and digital channels can drive growth, but R&D and marketing spend may pressure near‑term profitability.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.